🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

ctDNA-guided adj CTx escalation in stage III CRC #ASCO25 🔎Primary analysis of the ctDNA-positive cohort from the randomized AGITG DYNAMIC-III trial 👉mRFS 29 vs 36 mo 👉CTx escalation does not improve outcome 🧐 ctDNA very helpful to understand risk groups, but we need better

🚨CASSANDRA🚨 Resectable or BR PDAC 🔍 Neoadjuvant PAXG vs mFOLFIRINOX 🔥PAXG Demonstrates: ✅⬆️EFS ✅⬆️Path response ✅Suggestion of ⬆️OS Has PAXG supplanted FOLFIRINOX as the preferred neoadjuvant systemic tx for localized PDAC?? #ASCO25

💫 ADVANCEMENTS IN ONCOLOGY #AdvInOnc25 SignifyMD Delighted to join Oncology Brothers who are driving #MedEd and #SoMe forward through innovative podcasts and treatment algorithms for the practicing oncologist! 🤩A masterclass by Petros Grivas Enrique Grande highlighting

Impressive mPFS and HR results from the #JavelinMedley study at #ASCO25 — but unfortunately, no OS benefit yet with current follow-up. Toxicity is considerable for a maintenance setting, and beyond platinum response, no clear biomarker. Doesn’t look like an alternative to EV-P

Not just endpoints. Turning points. After median 9 years: NIVO+IPI shows durable OS, PFS & DOR superiority vs sunitinib in 1L aRCC. Robert Motzer MD #ASCO25 #cancer #oncology @oncoalert ASCO Kate Sears Toni Choueiri, MD Emre Yekedüz Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 silke gillessen

#ASCO25 #Plenary ASCO LBA1 - ATOMIC - mFOLFOX6 +\- atezoX1y in stage 3 dMMR colon cancer Alliance for Clinical Trials in Oncology n=712, 54% high-risk ➡️3yDFS 86.4% vs 76.7%, HR 0.50p<0.001 ➡️OS immature -2 deaths in combo arm 👏 Frank Sinicrope, MD Questions remain: 📌do we need FOLFOX? 📌 do we need 1

Durvalumab + FLOT in resectable GC/GEJ cancer #ASCO25 Plenary session 🔎MATTERHORN 👉mEFS n.r. vs 32.8, HR 0.71 👉mDFS n.r. vs 39.8 mo 👉OS n.r. in both arms, HR 0.78, not (yet) significant 👉pCR 19 vs 7% 🧐 Finally, ICI arrived in the peri-operative setting ESMO - Eur. Oncology

A standing ovation for #CHALLENGE trial at #ASCO25 - first in world to definitively show exercise reduces recurrence and improves survival: “For every 16 people, exercise prevents 1 person from recurrent/new cancer” “For every 14 people, exercise prevents 1 person from dying”

Big win in #HNSCC! Adding nivolumab to adjuvant CRT after surgery reduced recurrence risk by 24% in #NIVOPOSTOP (LBA2, #ASCO25): ASCO OncoAlert 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 gilberto lopes

⚡️ On Nature Medicine - Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial #BladderCancer #Immunotherapy Tom Powles Matt Galsky Joan Palou Redorta Evanguelos Xylinas Alberto Briganti Félix Guerrero-Ramos nature.com/articles/s4159…

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Geriatric assessment in older adults with acute myeloid leukemia: A Young International Society of Geriatric Oncology narrative review geriatriconcology.net/article/S1879-… Nina Rosa Neuendorff William Dale, MD, PhD, FASCO Cancer and Aging Research Group (CARG) #GeriOnc #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #Elsevier

10-year follow up for pembro in MSI-H/dMMR advanced solid tumors 🔎KEYNOTE 16 👉10-yrs OS rate: 46% 👉Rare progression after 2 years 👉We need biomarker to identify (non-) responders 🧐 Great to see 10yr survival data for systemic therapies ESMO - Eur. Oncology

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍OncoAlert ONCO BRUNO

🗣️Prostate Oral Abstract #ASCO25 👉LBA5006: Dr #GerhardtAttard presenting ABI +/- #Niraparib in #HRRdeficient mCSPC on #AMPLITUDE n = 696 pts 🧬germline / somatic HRR gene alterations - BRCA1/BRCA2 (55.6%) - BRIP1, CDK12, CHEK2, FANCA, PALB2, RAD51B, RAD54L (44.4%) high-vol

The most robust data post EVP in M1 bladder cancer by Michal Sternschuss MSKCC Carboplatin/gem was the commonest regimen #ASCO25 OncoAlert Results showed ⬆️ RRs than expected (50%) PFS =4.5 months & OS =11 months are good. 1st line gem/carbo OS was ~10 months previously?

Great presentation! Just to mention that we are also launching De-Escalate (EORTC 2238-GUCG) a pragmatic trial testing intermittent therapy in the good responders. We just opened the first centers. Anyone who is interested to participate please contact me or tombal

#ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are just a few of the top breast cancer studies presented, and some of the remaining questions.

Avelumab 1L maintenance vs best supportive care after platinum based chemo in advanced urothelial cancer; ⭐️Non-visceral mets: OS➡️31.4 vs 17.1 months (HR:0.6) and LN-only disease: OS➡️31.9 vs 22.7 months (HR:0.8) ⭐️Durable outcomes + manageable safety ➡️➡️still promising

The highlight of #ASCO25 was the AMPLITUDE trial presented by AttardLab on PARPi in HRR altered mHSPC. Listen to our podcast discussing these practice-changing data! spotifycreators-web.app.link/e/77hbNX73YTb